Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: A potential therapeutic target

Arthritis and Rheumatism

Volumn 65, Issue 12, 2013, Pages 3248-3258

  Rayavarapu, Sree ^a   Coley, William ^a   Van Der Meulen, Jack H ^a   Cakir, Erdinc ^a   Tappeta, Kathyayini ^a   Kinder, Travis B ^a   Dillingham, Blythe C ^a   Brown, Kristy J ^a   Hathout, Yetrib ^a   Nagaraju, Kanneboyina ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BORTEZOMIB; PROTEASOME; PROTEOME; STABLE ISOTOPE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; ENDOPLASMIC RETICULUM STRESS; GLYCOLYSIS; IMMUNOBLOTTING; IN VIVO STUDY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MOUSE; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCULAR DYSTROPHY; MYOSITIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; TANDEM MASS SPECTROMETRY; UBIQUITINATION;

ANIMALS; BORONIC ACIDS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; MICE; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSITIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

EID: 84888000313     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38180     Document Type: Article

References (42)

1. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824-35.
2. Vitadello M, Doria A, Tarricone E, Ghirardello A, Gorza L,. Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation. Arthritis Res Ther 2010; 12: R52.
3. Nogalska A, Engel WK, Askanas V,. Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers-possibly caused by endoplasmic reticulum stress. Neurosci Lett 2010; 474: 140-3
4. Vattemi G, Engel WK, McFerrin J, Askanas V,. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 2004; 164: 1-7.
5. Li CK, Knopp P, Moncrieffe H, Singh B, Shah S, Nagaraju K, et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009; 175: 1030-40.
6. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000; 97: 9209-14.
7. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1: 376-86.
8. Blagoev B, Kratchmarova I, Ong SE, Nielsen M, Foster LJ, Mann M,. A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat Biotechnol 2003; 21: 315-8.
9. Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 2008; 134: 353-64.
10. Sharma N, Medikayala S, Defour A, Rayavarapu S, Brown KJ, Hathout Y, et al. Use of quantitative membrane proteomics identifies a novel role of mitochondria in healing injured muscles. J Biol Chem 2012, 287: 30455-67.
11. Rayavarapu S, Coley W, Cakir E, Jahnke V, Takeda S, Aoki Y, et al. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Mol Cell Proteomics 2013; 12: 1061-73.
12. Baumeister W, Walz J, Zuhl F, Seemuller E,. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998; 92: 367-80.
13. Zhang A, Williamson CD, Wong DS, Bullough MD, Brown KJ, Hathout Y, et al. Quantitative proteomic analyses of human cytomegalovirus-induced restructuring of endoplasmic reticulum-mitochondrial contacts at late times of infection. Mol Cell Proteomics 2011; 10: M111.009936.
14. Alger HM, Rayavarapu S, Nagaraju K,. Measurement of activation of the endoplasmic reticulum stress response in autoimmune myositis. Methods Enzymol 2011; 489: 207-25.
15. Alger HM, Raben N, Pistilli E, Francia DL, Rawat R, Getnet D, et al. The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum 2011; 63: 3448-57.
16. Jahnke VE, van der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP, et al. Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet Muscle 2012; 2: 16.
17. Rayavarapu S, van der Meulen JH, Gordish-Dressman H, Hoffman EP, Nagaraju K, Knoblach SM,. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One 2010; 5: e12981.
18. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, et al. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009; 39: 591-602.
19. Coley W, Rayavarapu S, Pandey GS, Sabina RL, van der Meulen JH, Ampong B, et al. The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy. Arthritis Rheum 2012; 64: 3750-9.
20. Nader GA, Dastmalchi M, Alexanderson H, Grundtman C, Gernapudi R, Esbjornsson M, et al. A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med 2010; 16: 455-64.
21. Li J, Yin C, Okamoto H, Jaffe H, Oldfield EH, Zhuang Z, et al. proteomic analysis of inclusion body myositis. J Neuropathol Exp Neurol 2006; 65: 826-33.
22. Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67: 53-63.
23. Sela I, Milman Krentsis I, Shlomai Z, Sadeh M, Dabby R, Argov Z, et al. The proteomic profile of hereditary inclusion body myopathy. PLoS One 2011; 6: e16334.
24. Parker KC, Kong SW, Walsh RJ, Salajegheh M, Moghadaszadeh B, Amato AA, et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009; 39: 739-53.
25. Passadore I, Iadarola P, di Poto C, Giuliano S, Montecucco C, Cavagna L, et al. 2-DE and LC-MS/MS for a comparative proteomic analysis of BALf from subjects with different subsets of inflammatory myopathies. J Proteome Res 2009; 8: 2331-40.
26. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, et al. Ubiquitin hydrolase Uch-L1 rescues β-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006; 126: 775-88.
27. Nogalska A, Engel WK, McFerrin J, Kokame K, Komano H, Askanas V,. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem 2006; 96: 1491-9.
28. Henriques-Pons A, Nagaraju K,. Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol 2009; 21: 581-7.
29. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002; 157: 417-27.
30. Schwartz AL, Ciechanover A,. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009; 49: 73-96.
31. Ciechanover A, Brundin P,. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003; 40: 427-46.
32. Medina R, Wing SS, Goldberg AL,. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 1995; 307: 631-7.
33. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL,. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006; 58: 13-23.
34. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102: 303-10.
35. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-55.
36. Caron AZ, Haroun S, Leblanc E, Trensz F, Guindi C, Amrani A, et al. The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. BMC Musculoskelet Disord 2011; 12: 185.
37. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998; 95: 15671-6.
38. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A,. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004, 64: 4912-8.
39. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-28.
40. Thaloor D, Miller KJ, Gephart J, Mitchell PO, Pavlath GK,. Systemic administration of the NF-κB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 1999; 277: C320-9.
41. Jobin C, Hellerbrand C, Licato LL, Brenner DA, Sartor RB,. Mediation by NF-κB of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 1998; 42: 779-87.
42. Allport JR, Ding H, Collins T, Gerritsen ME, Luscinskas FW,. Endothelial-dependent mechanisms regulate leukocyte transmigration: a process involving the proteasome and disruption of the vascular endothelial-cadherin complex at endothelial cell-to-cell junctions. J Exp Med 1997; 186: 517-27.